Text Size

Drug Delivery and Toxicities of Adjuvant Chemotherapy in Resected NCSLC

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT00484016
First received: June 4, 2007
Last updated: February 19, 2013
Last verified: February 2013
History of Changes
  Purpose

There are limited numbers of retrospective studies showing the effectiveness of adjuvant chemotherapy over observation in resected lung cancers.


Condition Intervention
Adjuvant
Chemotherapy
Lung
Cancers
 Drug: Cisplatin/Docetaxel

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Drug Delivery and Toxicities of Adjuvant Chemotherapy in Resected NCSLC

Resource links provided by NLM:

MedlinePlus related topics: Cancer
U.S. FDA Resources

Further study details as provided by Washington University School of Medicine:

Enrollment: 45
Study Start Date: February 2006
Study Completion Date: April 2007
Primary Completion Date: April 2007 (Final data collection date for primary outcome measure)
Detailed Description:

We propose to retrospectively examine the Washington University School of Medicine experience on all patients receiving adjuvant chemotherapy between 2003 and 2005. We will retrospectively analyze the survival and outcomes in the lung cancer patients receiving adjuvant chemotherapy following surgical resection.

  Eligibility

Ages Eligible for Study:   18 Years to 88 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients that received adjuvant chemotherapy
  • 18-88 years

Exclusion Criteria:

  • Any patients that have not received adjuvant chemotherapy
  • Patients under 18 or over 88
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00484016

Sponsors and Collaborators
Washington University School of Medicine
Investigators
Principal Investigator: Ramaswamy Govindan, M.D. Washington University School of Medicine
  More Information

Additional Information:
Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine  This link exits the ClinicalTrials.gov site

Publications:

Responsible Party: Washington University School of Medicine
ClinicalTrials.gov Identifier: NCT00484016     History of Changes
Other Study ID Numbers: 06-0155
Study First Received: June 4, 2007
Last Updated: February 19, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Washington University School of Medicine:
adjuvant
chemotherapy
observation
resected
cancers

Additional relevant MeSH terms:
Adjuvants, Immunologic
Docetaxel
Cisplatin
Immunologic Factors
Physiological Effects of Drugs
 Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses
Radiation-Sensitizing Agents

ClinicalTrials.gov processed this record on May 22, 2013